East China’s Jiangsu province reported a year-on-year increase of 23.8% in its added value of the industrial enterprises above designated size in the first five months of the year, 6 percentage points higher than the national average, according to the latest industrial operation report released by the Provincial Department of Industry and Information Technology.
The report shows that the metallurgy, machinery, building materials, and light industry industries maintained a growth rate of about 40%, while the petrochemical, electronics, textile, and pharmaceutical industries maintained double-digit growth in the five-month period.
Stimulated by supply-side reforms and domestic and international circular development strategies, enterprises in Jiangsu have since the start of this year focus on cultivating products that are urgently needed at home and abroad, have broad market prospects, and have strong driving force.
Hansen Pharmaceutical Group Co., Ltd. is stepping up production of China's first original oral anti-hepatitis B virus drug "imitenofovir tablets" that was recently approved for marketing.
The latest statistics show that since the beginning of this year, enterprises above designated size in Jiangsu reported a year-on-year increase of 107.7% in the industrial profits. Fueled by the rapid growth in industrial investment, the province has fulfilled investment on 514 major industrial projects as scheduled. The province recorded 5,679 technological transformation projects in industrial information technology, an increase of 34.5% year on year. The planned investment of these investment projects will total 363.32 billion yuan, a year-on-year increase of 128.4%, providing a steady stream of power for continued growth.
